Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363667 | 0.87 | KDM4E (0.48) | GPR119PTPN2PTPN1PTPN6KDM4E | |
| Hydrochloric Acid SCHEMBL1362705 | 0.86 | KDM4E (0.47) | GPR119PTPN2PTPN1PTPN6KDM4E | |
| SCHEMBL4036422 | 0.85 | GPR119 (0.54) | GPR119SLC2A1KDM4EPKMFAAH | |
| SCHEMBL27233609 | 0.85 | GPR119 (0.55) | GPR119PTPN2PTPN1PTPN6KDM4E | |
| SCHEMBL27233615 | 0.85 | GPR119 (0.55) | GPR119USP30KDM4EPKM | |
| SCHEMBL6392640 | 0.83 | CYP46A1 (0.54) | CYP46A1HTR1AHTR1DHTR1BFAAH | |
| SCHEMBL18617673 | 0.82 | KDM4E (0.52) | GPR119KDM4EPKM | |
| SCHEMBL1364206 | 0.81 | HDAC1 (0.45) | GPR119SLC2A1USP30KDM4EPKM | |
| SCHEMBL1532820 | 0.81 | KDM4E (0.55) | GPR119USP30PTPN2PTPN1PTPN6 | |
| SCHEMBL14852116 | 0.81 | GPR119 (0.51) | GPR119KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | PROSIDION LIMITED (GB) | 2010-02-11 | — | — | US | claimed |
| EP-1838698-A1 | PYRIMIDINE DERIVATIVES AS GPCR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | claimed |
| WO-2006070208-A1 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS GPCR AGONISTS | PROSIDION LTD. (GB) | 2006-07-06 | — | — | WO | claimed |
| US-8173807-B2 | Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists | PROSIDION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-1838698-B1 | PYRIMIDINE DERIVATIVES AS GPCR AGONISTS | PROSIDION LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | PROSIDION LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-1838698-A1 | PYRIMIDINE DERIVATIVES AS GPCR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006070208-A1 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS GPCR AGONISTS | PROSIDION LTD. (GB) | 2006-07-06 | — | — | WO | disclosed |
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | GPR119 152/4885SLC2A1 821/4885CYP46A1 3835/4885 |
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | GPR119, GPR52, GPR65 | GPR119 1/4885SLC2A1 668/4885CYP46A1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.